Roflumilast

From WikiMD.org
Jump to navigation Jump to search

Roflumilast (pronounced roh-FLU-mi-last) is a phosphodiesterase-4 inhibitor used in the treatment of chronic obstructive pulmonary disease (COPD).

Etymology

The term "Roflumilast" is derived from the chemical name of the drug, which is 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide.

Usage

Roflumilast is primarily used to manage and reduce the risk of exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. It is often used when other medications have not been effective.

Mechanism of Action

Roflumilast works by inhibiting the activity of phosphodiesterase-4 (PDE4), an enzyme involved in the inflammatory response in the lungs. By blocking PDE4, roflumilast reduces inflammation, thereby reducing the frequency and severity of COPD exacerbations.

Side Effects

Common side effects of roflumilast include diarrhea, weight loss, nausea, headache, back pain, flu-like symptoms, and dizziness. Serious side effects may include mood changes, tremors, and unusual weight loss.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski